ArticleJAMA2022
Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021.
Article in JAMA, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Barriers to the Implementation of Acute Coronary Syndrome Guidelines in Healthcare: A Systematic Review.Reviews in cardiovascular medicine · 2026Pooled it
- Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.NEJM evidence · 2026Trial
- Effect of ventricular fibrillation on infarct size after myocardial infarction: a translational study.Basic research in cardiology · 2024Trial
- Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction - A post hoc analysis of the cel-02 phase IIa study.American heart journal · 2023Trial
- Transfer-workflow optimization in a regional chest pain center network reduces door-in-door-out time in ST-segment elevation myocardial infarction: An interrupted time-series study with spectral validation.International journal of cardiology. Heart & vasculature · 2026Article
- SIK2 antagonizes postinfarction cardiac repair by driving macrophage proinflammatory and impairing efferocytosis.Science advances · 2026Article
- Cardiac MR Characterization of Infarct-Related and Remote Myocardial Injury in Multivessel Disease After Acute Myocardial Infarction.Journal of magnetic resonance imaging : JMRI · 2026Article
- Characteristics and In-Hospital Outcomes of Self-Transport Patients With Acute Myocardial Infarction: A Nationwide Analysis.Circulation reports · 2026Article
- Persistent One-Year Mortality Gradient After STEMI and COVID-19: Long-Term Outcomes From the NACMI Registry.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Development and validation of a triglyceride-glucose index-based nomogram for predicting risk in STEMI patients undergoing primary PCI.BMC cardiovascular disorders · 2026Article
- An Evaluation of the Use of Fibrinolytic Therapy for Treatment of STEMI in Northern New England Over Two Decades.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- An association between epicardial adipose tissue and prognosis in acute myocardial infarction: a systematic review and meta-analysis.Journal of thoracic disease · 2026Article
- Temporal trends and prognostic impact of pre-hospital delay in ST-elevation myocardial infarction-20-year observational study from the SWEDEHEART registry.European heart journal. Acute cardiovascular care · 2026Observational
- Early Inflammatory Biomarkers, Ventricular Dysfunction and In-Hospital Mortality in Patients with ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.Diagnostics (Basel, Switzerland) · 2026Article
- Trends in characteristics and outcomes following primary percutaneous coronary intervention: insights from a nationwide analysis.BMC cardiovascular disorders · 2026Article
- Pre-Hospital Delay in STEMI: A Narrative Review of Symptom Onset-to-First Medical Contact Across High-Income and Low- and Middle-Income Countries.Clinical cardiology · 2026Review
- Implementing the GWTG-CAD Program in Mexico: Feasibility, Challenges and Lessons Learned for Acute and Secondary Prevention and Management.Journal of the American Heart Association · 2026Article
- Article
- Heart Failure Quality of Care Among Asian Patients in the United States.Journal of the American College of Cardiology · 2026Article
- Racial Disparities in Door-to-Clinician Time for Cardiac Chest Pain in the Emergency Department.The western journal of emergency medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 10 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Recognizing the association between timely treatment and less myocardial injury for patients with ST-segment elevation myocardial infarction (STEMI), US national guidelines recommend specific treatment-time goals. Objective: To describe these process measures and outcomes for a recent cohort of patients. Design, Setting, and Participants: Cross-sectional study of a diagnosis-based registry between the second quarter of 2018 and the third quarter of 2021 for 114 871 patients with STEMI treated at 648 hospitals in the Get With The Guidelines-Coronary Artery Disease registry. Exposures: STEMI or STEMI equivalent. Main Outcomes and Measures: Treatment times, in-hospital mortality, and adherence to system goals (75% treated ≤90 minutes of first medical contact if the first hospital is percutaneous coronary intervention [PCI]-capable and ≤120 minutes if patients require transfer to a PCI-capable hospital). Results: In the study population, median age was 63 (IQR, 54-72) years, 71% were men, and 29% were women. Median time from symptom onset to PCI was 148 minutes (IQR, 111-226) for patients presenting to PCI-capable hospitals by emergency medical service, 195 minutes (IQR, 127-349) for patients walking in, and 240 minutes (IQR, 166-402) for patients transferred from another hospital. Adjusted in-hospital mortality was lower for those treated within target times vs beyond time goals for patients transported via emergency medical services (first medical contact to laboratory activation ≤20 minutes [in-hospital mortality, 3.6 vs 9.2] adjusted OR, 0.54 [95% CI, 0.48-0.60], and first medical contact to device ≤90 minutes [in-hospital mortality, 3.3 vs 12.1] adjusted OR, 0.40 [95% CI, 0.36-0.44]), walk-in patients (hospital arrival to device ≤90 minutes [in-hospital mortality, 1.8 vs 4.7] adjusted OR, 0.47 [95% CI, 0.40-0.55]), and transferred patients (door-in to door-out time <30 minutes [in-hospital mortality, 2.9 vs 6.4] adjusted OR, 0.51 [95% CI, 0.32-0.78], and first hospital arrival to device ≤120 minutes [in-hospital mortality, 4.3 vs 14.2] adjusted OR, 0.44 [95% CI, 0.26-0.71]). Regardless of mode of presentation, system goals were not met in most quarters, with the most delayed system performance among patients requiring interhospital transfer (17% treated ≤120 minutes). Conclusions and Relevance: This study of patients with STEMI included in a US national registry provides information on changes in process and outcomes between 2018 and 2021.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.